SOLIGENIX, INC. Form 8-K Summary
Business Context and Reporting Period
Soligenix, Inc. (SNGX), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on January 23, 2026. The filing discloses the execution of an At Market Issuance Sales Agreement to raise capital through the sale of common stock.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The primary financial data point disclosed is the authorization to sell shares with an aggregate offering price of up to $3,450,000.
Material Changes and Transaction Details
- Sales Agreement: Entered into an agreement with Rodman & Renshaw, LLC to sell common stock via an "at-the-market" offering.
- Offering Size: Up to $3,450,000 in aggregate gross proceeds.
- Commission: The Company will pay a fixed commission of up to 3.0% of gross proceeds to the sales agent.
- Termination Date: The offering terminates on the earliest of December 15, 2026, the sale of all shares, or termination by either party.
- Flexibility: The Company retains the right to set sale parameters, including price floors and daily volume limits, and may suspend sales at any time.
Guidance, Outlook, and Risks
The filing explicitly states that the Company cannot provide assurances that it will issue any shares under the agreement. The agreement may be terminated in the event of a material adverse change in the Company. No specific operational guidance or future financial outlook was provided in this document.
Investor Verification Checklist
- Verify the current market price of SNGX to assess potential dilution from the $3,450,000 offering.
- Review the Company's most recent 10-K or 10-Q to determine current cash runway and liquidity needs.
- Confirm the status of the underlying shelf registration statement (File No. 333-274265) and any subsequent amendments.
- Monitor future filings to track the actual volume of shares sold and proceeds generated under this agreement.